(Q43596063)

25 November 2017

title

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies (English)

1 reference

25 November 2017

1

Barry D Hock

1 reference

25 November 2017

2

Judith L McKenzie

1 reference

25 November 2017

5

Karen Taylor

1 reference

25 November 2017

7

Hagop Kantarjian

1 reference

25 November 2017

8

Francis Giles

1 reference

25 November 2017

9

Maher Albitar

1 reference

25 November 2017

Nigel W Patton

3

1 reference

25 November 2017

Mark Drayson

series ordinal

4

1 reference

25 November 2017

Chris Wakeman

series ordinal

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

25 November 2017

1 reference

25 November 2017

volume

106

1 reference

25 November 2017

issue

10

1 reference

25 November 2017

page(s)

2148-2157

1 reference

Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Differential regulation of cell survival by CD40

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Prospects for CD40-directed experimental therapy of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

The role of the CD40 pathway in the pathogenesis and treatment of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Phase I study of recombinant human CD40 ligand in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

A novel blocking monoclonal antibody recognizing a distinct epitope of human CD40 molecule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Membrane-anchored CD40 Is Processed by the Tumor Necrosis Factor-α-converting Enzyme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21816

7 January 2021

Identifiers

DOI

10.1002/CNCR.21816

1 reference

25 November 2017

1 reference